Options for MRD Testing Affect Patient Treatment Plan in Lung Cancer
Luis E. Raez, MD, discusses when minimal residual disease testing can be performed as an option for patients with lung cancer.
Related Articles
A Pioneering Journey in Radiation Oncology Inspired by Multidisciplinary Collaboration
Fueled by wanting to carry on his father’s legacy, Ralph R. Weichselbaum, MD, created his own mark on radiation therapy in oncologic care.
New Advances in Waldenström Macroglobulinemia
Understanding Waldenström Macroglobulinemia, and genomic profiles influencing clinical presentation and treatment strategies.
Debate: What Is the Best Posttransplant Follow-Up – Maintenance vs Close Monitoring With Laboratory Testing
Panelists debate the best posttransplant follow-up approach for acute myeloid leukemia, weighing the benefits of maintenance therapy vs close monitoring with regular laboratory testing to…
Ohio State’s Update From the 2024 San Antonio Breast Cancer Symposium 02/01/2025
Breast cancer experts from Ohio State and invited speakers will bring you the latest insights and practical guidance as presented at the 2024 San Antonio…
Dr Riess on the Investigation of Ivonescimab in Advanced NSCLC
Jonathan Wesley Riess, MD, MS, discusses data from the phase 3 HARMONi-2 trial evaluating ivonescimab vs pembrolizumab in advanced NSCLC.
Community Practice Training During Fellowship Often Falls Short
A hematology fellow discusses findings from 2 surveys he coauthored, which sought to identify gaps in community practice training during hematology/oncology fellowship.
Richard Pazdur, FDA Cancer Chief, Discusses 25 Years of Innovation
Dr. Richard Pazdur for 25 years has overseen innovations in the treatment of deadly diseases at the agency.
Transplant and Nontransplant Salvage Therapy in Pediatric Relapsed or Refractory Hodgkin Lymphoma
This nonrandomized clinical trial in pediatric relapsed classic Hodgkin lymphoma tested fludeoxyglucose-18 positron emission tomography scans to identify patients in whom transplant-free salvage therapy would…
Subcutaneous Isatuximab Combo Hits Primary End Points in Phase 3 Trial
The phase 3 IRAKLIA trial of subcutaneous isatuximab met its co-primary end points in multiple myeloma.